GLIMEPIRIDE METFORMIN MARKET

INTRODUCTIONGLIMEPIRIDE METFORMIN MARKET

Glimepiride + Metformin is a combination of two antidiabetic medicines: Glimepiride and Metformin. Glimepiride is a sulfonylurea which works by increasing the amount of insulin released by the pancreas in order to lower the blood glucose.

Metformin is a biguanide which works by lowering glucose production in the liver, delaying glucose absorption from intestines and increasing the body's sensitivity to insulin.

The use of Glimepiride+Metformin can lead to lactic acidosis. It is a medical emergency which is caused by increased levels of lactic acid in the blood. It is also known as MALA (Metformin-associated lactic acidosis).

It is a rare side effect associated with the use of metformin and therefore, it is considered to be harmful for patients with underlying kidney disease, old age patients or who take large amounts of alcohol.

Symptoms of lactic acidosis may include muscle pain or weakness, dizziness, tiredness, feeling of cold in arms and legs, difficulty in breathing, nausea, vomiting, stomach pain or slow heart rate.

It improves blood glucose levels in adults when taken along with proper diet and regular exercise. Glimepiride lowers the blood glucose levels by increasing the release of insulin from the pancreas.

Metformin works by lowering the glucose production in the liver and improving insulin sensitivity. This combination is not indicated for the treatment of type 1 DM.

GLIMEPIRIDE METFORMIN MARKET SIZE AND FORECAST

The Global glimepiride metformin market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.

GLIMEPIRIDE METFORMIN MARKETNEW PRODUCT LAUNCH

Dailyglim-M2 Forte - Dailyglim-M2 Forte Tablet 10's belongs to a class of medicines called anti-diabetic drugs used in the treatment of type 2 diabetes, especially in patients whose blood sugar levels are not controlled by diet and exercise alone.

Type 2 diabetes is a chronic (long-lasting) condition that affects the way our body processes glucose. People with type 2 diabetes either do not produce enough insulin, or the insulin produced is unable to perform its function in the body (insulin resistance).

Dailyglim-M2 Forte Tablet 10's is a combination of two antidiabetic drugs, namely: Glimepiride and Metformin. Glimepiride works by stimulating beta cells in the pancreas that produce insulin.

Thus, insulin helps to remove sugar from the blood. Metformin PR is a prolonged-release formulation that releases the drug in smaller portions over a longer duration of time.

Metformin works by reducing the sugar production by cells in the liver and delays sugar absorption from the intestines. Also, it increases the sensitivity of muscle cells to insulin which enables these cells to remove sugar more effectively from the blood.

GLIMEPIRIDE METFORMIN MARKETCOMPANY PROFILE

• Dailyglim
• Emcure pharma
• MK Pharma
• Varuna medicines
• PRD

THISGLIMEPIRIDE METFORMIN MARKETREPORT WILL ANSWER FOLLOWING QUESTIONS

1. How many glimepiride metformin are manufactured per annum globally? Who are the sub-component suppliers in different regions?
2. Cost breakup of a Global glimepiride metformin and key vendor selection criteria
3. Where is the glimepiride metformin manufactured? What is the average margin per unit?
4. Market share of Global glimepiride metformin market manufacturers and their upcoming products
5. Cost advantage for OEMs who manufacture Global glimepiride metformin in-house
6. key predictions for next 5 years in Global glimepiride metformin market
7. Average B-2-B glimepiride metformin market price in all segments
8. Latest trends in glimepiride metformin market, by every market segment
9. The market size (both volume and value) of the glimepiride metformin market in 2024-2030 and every year in between?
10. Production breakup of glimepiride metformin market, by suppliers and their OEM relationship